Our commitment is to bring personalized and predictive medicine to everyone and to enhance global healthcare.
A better global healthcare must not be a reality only for the wealthy. Individuals living in poor and dire situations should be a priority for everyone working in the healthcare industry.
Our disruptive technology is one of the best solutions in countries where the cost of drug treatment makes it impossible to treat enough people.
With an effectively limited healthcare budget, we believe strongly that wide screening programs must be better organized in order to identify the priority cases.
Identifying people at risk of developing liver cancer and cirrhosis in Africa, Asia and South America could save millions of lives of patients infected with schistosomiasis.
Schistosomiasis, also known as bilharzia, is a chronic disease caused by parasitic worms that live in certain types of fresh water snails. After Malaria, Schistosomiasis is the second most devastating parasitic disease in tropical countries. In sub-Saharan Africa, more than 200,000 deaths per year are caused by schistosomiasis. Depending on the species of the parasite, schistosomiasis causes liver and intestinal diseases.
Bilhi Genetics, in partnership with leading research institutes, foundations and NGOs is currently trying to organize wide screening programs in Africa and Asia to identify individuals with a high risk of developing liver fibrosis in order to treat them manually with existing anti-bilharzia treatment.
This program aims at drastically decreasing the number of deaths caused by schistosomiasis.
For any further information please contact us.